Zacks Company Profile for X4 Pharmaceuticals, Inc. (XFOR : NSDQ) |
|
|
|
Company Description |
X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.
Number of Employees: 83 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $1.16 |
Daily Weekly Monthly
 |
20 Day Moving Average: 156,471 shares |
Shares Outstanding: 30.82 (millions) |
Market Capitalization: $35.76 (millions) |
Beta: 0.62 |
52 Week High: $9.90 |
52 Week Low: $1.00 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-10.08% |
1.27% |
12 Week |
-27.04% |
-19.80% |
Year To Date |
-49.35% |
-34.91% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Paula Ragan - President and Chief Executive Officer
Michael S. Wyzga - Chairman of the Board of Directors
Adam S. Mostafa - Chief Financial Officer and Treasurer
William E. Aliski - Director
Gary J. Bridger - Director
|
|
Peer Information
X4 Pharmaceuticals, Inc. (CORR.)
X4 Pharmaceuticals, Inc. (RSPI)
X4 Pharmaceuticals, Inc. (CGXP)
X4 Pharmaceuticals, Inc. (BGEN)
X4 Pharmaceuticals, Inc. (GTBP)
X4 Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98420X103
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
|
|
Share - Related Items
Shares Outstanding: 30.82
Most Recent Split Date: 3.00 (0.17:1)
Beta: 0.62
Market Capitalization: $35.76 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.66 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-2.43 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/02/22 |
|
|
|
|